World News

The companies unveiled their partnership at the 2026 J.P. Morgan Healthcare Conference, which took place from January 12 to 15 in San Francisco.

This new 35,000 square foot, purpose-built site represents Novartis’s fourth dedicated RLT facility.

Nimbus will leverage its specialized expertise in computational chemistry and structure-based drug design to discover a small molecule drug candidate.

Terumo plans to distribute the product to hospitals, clinics, and emergency care settings nationwide, making the technology widely accessible to medical professionals who perform injections daily.

The NMPA based its decision on compelling evidence from the TRIDENT-1 study, a pivotal Phase I/II clinical trial that demonstrated the drug’s effectiveness over time.

The sale came about following an unsolicited offer from BGH Capital, which focuses on investments in Australia and New Zealand.

The deal collapsed after STAAR failed to secure sufficient shareholder approval during a special stockholders meeting held on January 6.

Amgen’s latest acquisition is centered on Dark Blue’s lead candidate, DBT 3757, which specifically treats acute myeloid leukemia that affects bone marrow and blood cells.

Sanofi will leverage Earendil’s artificial intelligence (AI)-powered drug discovery platform to support the design and development of multiple new therapeutic assets.

The collaboration aimed to support the distribution of Valneva’s single-dose vaccine, Ixchiq, in low- and middle-income countries (LMICs) across Asia.